-
Something wrong with this record ?
Mechanism of action and efficacy of RX-111, a thieno[2,3-c]pyridine derivative and small molecule inhibitor of protein interaction with glycosaminoglycans (SMIGs), in delayed-type hypersensitivity, TNBS-induced colitis and experimental autoimmune encephalomyelitis
N. Harris, J. Koppel, F. Zsila, S. Juhas, G. Il'kova, FY. Kogan, O. Lahmy, G. Wildbaum, N. Karin, R. Zhuk, P. Gregor,
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2002-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2011-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2002-01-01 to 1 year ago
- MeSH
- Anti-Inflammatory Agents pharmacology therapeutic use MeSH
- Myelin Basic Protein immunology MeSH
- Encephalomyelitis, Autoimmune, Experimental drug therapy immunology MeSH
- Human Umbilical Vein Endothelial Cells drug effects immunology MeSH
- Heparitin Sulfate metabolism MeSH
- Colitis chemically induced drug therapy immunology MeSH
- Rats MeSH
- Trinitrobenzenesulfonic Acid MeSH
- Humans MeSH
- Mice, Inbred BALB C MeSH
- Cell Line, Tumor MeSH
- Oxazolone MeSH
- Rats, Inbred Lew MeSH
- Hypersensitivity, Delayed chemically induced drug therapy immunology MeSH
- Pyridines pharmacology therapeutic use MeSH
- Leukocyte Rolling drug effects MeSH
- T-Lymphocytes drug effects immunology MeSH
- Thiophenes pharmacology therapeutic use MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
OBJECTIVE AND DESIGN: Elucidate the mechanism of action of the small molecule inhibitor of protein binding to glycosaminoglycans, RX-111 and assay its anti-inflammatory activity in animal models of inflammatory disease. MATERIALS: The glycosaminoglycan, heparin, was used in the mechanism of action study of RX-111. Human T lymphocytes and umbilical vein endothelial cells were used to assay the in vitro activity of RX-111. Mouse and rat models of disease were used to assay the anti-inflammatory activity of RX-111 in vivo. METHODS: Circular dichroism and UV/Vis absorption spectroscopy were used to study the binding of RX-111 to the glycosaminoglycan, heparin. T lymphocyte rolling on endothelial cells under shear flow was used to assay RX-111 activity in vitro. Delayed-type hypersensitivity (DTH) and tri-nitrobenzene sulfonic acid (TNBS)-induced colitis in mice and experimental autoimmune encephalomyelitis (EAE) in rats were used to assay anti-inflammatory activity of RX-111 in vivo. RESULTS: RX-111 was shown to bind directly to heparin. It inhibited leukocyte rolling on endothelial cells under shear flow and reduced inflammation in the mouse model of DTH. RX-111 was efficacious in the mouse model of inflammatory bowel disease, TNBS-induced colitis and the rat model of multiple sclerosis, EAE. CONCLUSIONS: RX-111 exercises its broad spectrum anti-inflammatory activity by a singular mechanism of action, inhibition of protein binding to the cell surface GAG, heparan sulfate. RX-111 and related thieno[2,3-c]pyridine derivatives are potential therapeutics for the treatment of inflammatory and autoimmune diseases.
Department of Immunology Rappaport Institute Rappaport Faculty of Medicine Technion Haifa Israel
Institute of Animal Physiology Slovak Academy of Sciences 04001 Kosice Slovakia
Rimonyx Pharmaceuticals Ltd Rabin Science Park 70400 Ness Ziona Israel
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17000606
- 003
- CZ-PrNML
- 005
- 20170118112119.0
- 007
- ta
- 008
- 170103s2016 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00011-016-0915-4 $2 doi
- 024 7_
- $a 10.1007/s00011-016-0915-4 $2 doi
- 035 __
- $a (PubMed)26794621
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Harris, Nicholas $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel. nharris@braude.ac.il. Ephraim Katzir Department of Biotechnology Engineering, ORT Braude Academic College of Engineering, 21982, Karmiel, Israel. nharris@braude.ac.il.
- 245 10
- $a Mechanism of action and efficacy of RX-111, a thieno[2,3-c]pyridine derivative and small molecule inhibitor of protein interaction with glycosaminoglycans (SMIGs), in delayed-type hypersensitivity, TNBS-induced colitis and experimental autoimmune encephalomyelitis / $c N. Harris, J. Koppel, F. Zsila, S. Juhas, G. Il'kova, FY. Kogan, O. Lahmy, G. Wildbaum, N. Karin, R. Zhuk, P. Gregor,
- 520 9_
- $a OBJECTIVE AND DESIGN: Elucidate the mechanism of action of the small molecule inhibitor of protein binding to glycosaminoglycans, RX-111 and assay its anti-inflammatory activity in animal models of inflammatory disease. MATERIALS: The glycosaminoglycan, heparin, was used in the mechanism of action study of RX-111. Human T lymphocytes and umbilical vein endothelial cells were used to assay the in vitro activity of RX-111. Mouse and rat models of disease were used to assay the anti-inflammatory activity of RX-111 in vivo. METHODS: Circular dichroism and UV/Vis absorption spectroscopy were used to study the binding of RX-111 to the glycosaminoglycan, heparin. T lymphocyte rolling on endothelial cells under shear flow was used to assay RX-111 activity in vitro. Delayed-type hypersensitivity (DTH) and tri-nitrobenzene sulfonic acid (TNBS)-induced colitis in mice and experimental autoimmune encephalomyelitis (EAE) in rats were used to assay anti-inflammatory activity of RX-111 in vivo. RESULTS: RX-111 was shown to bind directly to heparin. It inhibited leukocyte rolling on endothelial cells under shear flow and reduced inflammation in the mouse model of DTH. RX-111 was efficacious in the mouse model of inflammatory bowel disease, TNBS-induced colitis and the rat model of multiple sclerosis, EAE. CONCLUSIONS: RX-111 exercises its broad spectrum anti-inflammatory activity by a singular mechanism of action, inhibition of protein binding to the cell surface GAG, heparan sulfate. RX-111 and related thieno[2,3-c]pyridine derivatives are potential therapeutics for the treatment of inflammatory and autoimmune diseases.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antiflogistika $x farmakologie $x terapeutické užití $7 D000893
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a kolitida $x chemicky indukované $x farmakoterapie $x imunologie $7 D003092
- 650 _2
- $a encefalomyelitida autoimunitní experimentální $x farmakoterapie $x imunologie $7 D004681
- 650 _2
- $a heparitinsulfát $x metabolismus $7 D006497
- 650 _2
- $a endoteliální buňky pupečníkové žíly (lidské) $x účinky léků $x imunologie $7 D061307
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a pozdní přecitlivělost $x chemicky indukované $x farmakoterapie $x imunologie $7 D006968
- 650 _2
- $a rolling leukocytů $x účinky léků $7 D036904
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši inbrední BALB C $7 D008807
- 650 _2
- $a encefalitogenní základní proteiny $x imunologie $7 D004676
- 650 _2
- $a oxazolon $7 D010081
- 650 _2
- $a pyridiny $x farmakologie $x terapeutické užití $7 D011725
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani inbrední LEW $7 D011917
- 650 _2
- $a T-lymfocyty $x účinky léků $x imunologie $7 D013601
- 650 _2
- $a thiofeny $x farmakologie $x terapeutické užití $7 D013876
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a kyselina trinitrobenzensulfonová $7 D014302
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Koppel, Juraj $u Institute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia.
- 700 1_
- $a Zsila, Ferenc $u Biomolecular Self-Assembly Group, Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Budapest, Hungary.
- 700 1_
- $a Juhas, Stefan $u Institute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia. Institute of Animal Physiology and Genetics of the ASCR, v. v. i., Rumburská 89, 277 21, Liběchov, Czech Republic.
- 700 1_
- $a Il'kova, Gabriela $u Institute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia. GYN-FIV a.s., Záhradnícka 42, 821 085, Bratislava, Slovakia.
- 700 1_
- $a Kogan, Faina Yurgenzon $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel.
- 700 1_
- $a Lahmy, Orly $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel.
- 700 1_
- $a Wildbaum, Gizi $u Department of Immunology, Rappaport Institute, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
- 700 1_
- $a Karin, Nathan $u Department of Immunology, Rappaport Institute, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
- 700 1_
- $a Zhuk, Regina $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel.
- 700 1_
- $a Gregor, Paul $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel. paul@gismotherapeutics.com. GISMO Therapeutics Inc., A253 ASTECC-UK, Lexington, KY, 40506, USA. paul@gismotherapeutics.com.
- 773 0_
- $w MED00002242 $t Inflammation research official journal of the European Histamine Research Society ... [et al.] $x 1420-908X $g Roč. 65, č. 4 (2016), s. 285-94
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26794621 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170103 $b ABA008
- 991 __
- $a 20170118112226 $b ABA008
- 999 __
- $a ok $b bmc $g 1179746 $s 961173
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 65 $c 4 $d 285-94 $e 20160121 $i 1420-908X $m Inflammation research $n Inflamm Res $x MED00002242
- LZP __
- $a Pubmed-20170103